FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eike Gallmeier

Research Profile

Anatomy

Chemicals & Drugs

Disorders

Living Beings

Physiology

Co-author Network

Publications

TOP 3
Eike Gallmeier; Burkhard Göke; Thomas Kirchner; Lydia Kriegl; Hendrik Seeliger; Dominik C Bader; Sabina Berezowska; Christiane Bruns; Enrico N De Toni
Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.
Claus Schäfer; Hendrik Seeliger; Andreas Ziesch; Gerald Assmann; Dominik C Bader; Christiane Bruns; Denise Buchner; Enrico N De Toni; Burkhard Göke; Yang Guo; Andreas Jung; Thomas Kirchner; Rüdiger P Laubender; Stephanie Ochs; Andreas Palagyi; Eike Gallmeier
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
Lydia Kriegl; Antonia Rizzani; Eike Gallmeier; Alexander L Gerbes; Burkhard Göke; Heiko Hermeking; David Horst; Rene Jackstadt; Andreas Jung; Thomas Kirchner; Enrico N De Toni
Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eike Gallmeier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Eike Gallmeier; Burkhard Göke; Thomas Kirchner; Lydia Kriegl; Hendrik Seeliger; Dominik C Bader; Sabina Berezowska; Christiane Bruns; Enrico N De Toni
Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.
PloS one 2013;8(2):e56760.
2012: Claus Schäfer; Hendrik Seeliger; Andreas Ziesch; Gerald Assmann; Dominik C Bader; Christiane Bruns; Denise Buchner; Enrico N De Toni; Burkhard Göke; Yang Guo; Andreas Jung; Thomas Kirchner; Rüdiger P Laubender; Stephanie Ochs; Andreas Palagyi; Eike Gallmeier
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
Journal of cellular and molecular medicine 2012;16(8):1776-91.
2012: Lydia Kriegl; Antonia Rizzani; Eike Gallmeier; Alexander L Gerbes; Burkhard Göke; Heiko Hermeking; David Horst; Rene Jackstadt; Andreas Jung; Thomas Kirchner; Enrico N De Toni
Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.
PloS one 2012;7(12):e51654.
2011: Eike Gallmeier; Patrick C Hermann; Maria-Theresa Mueller; Juan G Machado; Andreas Ziesch; Enrico N De Toni; Andreas Palagyi; Christian Eisen; Joachim W Ellwart; Jose Rivera; Belen Rubio-Viqueira; Manuel Hidalgo; Fred Bunz; Burkhard Göke; Christopher Heeschen
Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.
Stem cells (Dayton, Ohio) 2011;29(3):418-29.
2011: Tomas Hucl; Eike Gallmeier
DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target.
Physiological research / Academia Scientiarum Bohemoslovaca 2011;60(3):453-65.
2010: Lydia Kriegl; Andreas Jung; Jutta Engel; Rene Jackstadt; Alexander L Gerbes; Eike Gallmeier; Jana Anni Reiche; Heiko Hermeking; Antonia Rizzani; Christiane J Bruns; Frank T Kolligs; Thomas Kirchner; Burkhard Göke; Enrico N De Toni
Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(22):5529-38.
2010: Andreas Palagyi; Kornelia Neveling; Ursula Plinninger; Andreas Ziesch; Bianca-Sabrina Targosz; Gerald U Denk; Stephanie Ochs; Antonia Rizzani; Daniel Meier; Wolfgang E Thasler; Helmut Hanenberg; Enrico N De Toni; Florian Bassermann; Claus Schäfer; Burkhard Göke; Detlev Schindler; Eike Gallmeier
Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.
Molecular cancer 2010;9():127.
2009: Yong-Yu Li; Stephanie Ochs; Zhi-Rong Gao; A Malo; Chang-Jie Chen; Shuai Lv; Eike Gallmeier; Burkhard Göke; Claus Schäfer
Regulation of HSP60 and the role of MK2 in a new model of severe experimental pancreatitis.
American journal of physiology. Gastrointestinal and liver physiology 2009;297(5):G981-9.
2009: S R Mucha; A Rizzani; Alexander L Gerbes; P Camaj; Wolfgang E Thasler; C J Bruns; Sören Eichhorst; Eike Gallmeier; Frank T Kolligs; Burkhard Göke; Enrico N De Toni
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.
Gut 2009;58(5):688-98.
2009: Stefan Boeck; Klaus Metzeler; Andreas Hausmann; Anja Baumann; Eike Gallmeier; Klaus G Parhofer; Hans-Joachim Stemmler
Cisplatin-based chemotherapy for pulmonary metastasized germ cell tumors of the testis--be aware of acute respiratory distress syndrome.
Onkologie 2009;32(3):125-8.
2008: Tomas Hucl; Carlo Rago; Eike Gallmeier; Jonathan R Brody; Myriam Gorospe; Scott E Kern
A syngeneic variance library for functional annotation of human variation: application to BRCA2.
Cancer research 2008;68(13):5023-30.
2008: Jordan M Winter; Angela H Ting; Felip Vilardell; Eike Gallmeier; Stephen B Baylin; Ralph Hruban; Scott E Kern; Christine A Iacobuzio-Donahue
Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):412-8.
2007: Tomas Hucl; Jonathan R Brody; Eike Gallmeier; Christine A Iacobuzio-Donahue; Iain K G Farrance; Scott E Kern
High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif.
Cancer research 2007;67(19):9055-65.
2007: HIROYUKI KONISHI; Bedri Karakas; Abde M Abukhdeir; Josh David Lauring; John P Gustin; Joseph P Garay; Yuko Konishi; Eike Gallmeier; Kurtis E Bachman; Ben Ho Park
Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
Cancer research 2007;67(18):8460-7.
2007: Steven C Cunningham; Eike Gallmeier
Supraclavicular approach for central venous catheterization: "safer, simpler, speedier".
Journal of the American College of Surgeons 2007;205(3):514-6; author reply 516-7.
2007: Tomas Hucl; Eike Gallmeier; Scott E Kern
Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.
Cell cycle (Georgetown, Tex.) 2007;6(11):1336-41.
2007: Eike Gallmeier; Tomas Hucl; Eric S Calhoun; Steven C Cunningham; Fred Bunz; Jonathan R Brody; Scott E Kern
Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.
Cancer biology & therapy 2007;6(5):654-60.
2007: Eike Gallmeier; Tomas Hucl; Jonathan R Brody; David A Dezentje; Khola Tahir; Jana Kasparkova; Viktor Brabec; Kurtis E Bachman; Scott E Kern
High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Cancer research 2007;67(5):2169-77.
2007: Eike Gallmeier; Scott E Kern
Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):4-10.
2006: Eric S Calhoun; Eike Gallmeier; Steven C Cunningham; James R Eshleman; Ralph Hruban; Scott E Kern
Copy-number methods dramatically underestimate loss of heterozygosity in cancer.
Genes, chromosomes & cancer 2006;45(11):1070-1.
2006: Jonathan R Brody; Tomas Hucl; Eike Gallmeier; Jordan M Winter; Scott E Kern; KATHLEEN MURPHY
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
Cancer research 2006;66(19):9369-73.
2006: Eric S Calhoun; Tomas Hucl; Eike Gallmeier; Kristen M West; Dan E Arking; Anirban Maitra; Christine A Iacobuzio-Donahue; Aravinda Chakravarti; Ralph Hruban; Scott E Kern
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
Cancer research 2006;66(16):7920-8.
2006: Jonathan R Brody; Eike Gallmeier; Kiyoshi Yoshimura; Tomas Hucl; Piotr Kulesza; Marcia Canto; Ralph Hruban; Richard D Schulick; Scott E Kern
A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes.
Cancer biology & therapy 2006;5(8):923-7.
2006: Eike Gallmeier; Eric S Calhoun; Carlo Rago; Jonathan R Brody; Steven C Cunningham; Tomas Hucl; Myriam Gorospe; Manu Kohli; Christoph Lengauer; Scott E Kern
Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gastroenterology 2006;130(7):2145-54.
2006: Steven C Cunningham; Eike Gallmeier; Tomas Hucl; David A Dezentje; Eric S Calhoun; Geppino Falco; Kotb Abdelmohsen; Myriam Gorospe; Scott E Kern
Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss.
Cancer research 2006;66(11):5560-4.
2006: Steven C Cunningham; Eike Gallmeier; Tomas Hucl; David A Dezentje; Kotb Abdelmohsen; Myriam Gorospe; Scott E Kern
Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
Cell cycle (Georgetown, Tex.) 2006;5(10):1090-3.
2005: Michiel S van der Heijden; Jonathan R Brody; David A Dezentje; Eike Gallmeier; Steven C Cunningham; Michael J Swartz; Angelo M DeMarzo; G Johan A Offerhaus; William H Isacoff; Ralph Hruban; Scott E Kern
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7508-15.
2005: Eike Gallmeier; Jordan M Winter; Steven C Cunningham; Saeed R Kahn; Scott E Kern
Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX.
Carcinogenesis 2005;26(10):1811-20.
2005: Eike Gallmeier; Scott E Kern
Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition.
Cancer biology & therapy 2005;4(7):703-6.
2005: Eike Gallmeier; Claus Schäfer; P Moubarak; Anne Barbara Tietz; I Plössl; Ralf Huss; Burkhard Göke; Andreas C C Wagner
JAK and STAT proteins are expressed and activated by IFN-gamma in rat pancreatic acinar cells.
Journal of cellular physiology 2005;203(1):209-16.
2004: Jonathan R Brody; Eric S Calhoun; Eike Gallmeier; Talisa D Creavalle; Scott E Kern
Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media.
BioTechniques 2004;37(4):598, 600, 602.
2004: Michiel S van der Heijden; Jonathan R Brody; Eike Gallmeier; Steven C Cunningham; David A Dezentje; Dong Shen; Ralph Hruban; Scott E Kern
Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
The American journal of pathology 2004;165(2):651-7.
2004: I Ploessl; Eike Gallmeier; C Schaefer; Manfred Bilzer; Iris Bittmann; Burkhard Göke; Andreas C C Wagner
ANP preconditioning does not increase protection against experimental pancreatitis, observed after general anesthesia and jugular vein catheterization.
Pancreas 2004;28(2):166-73.
2003: Gerald Ulrich Denk; Karl-Heinz Bergstermann; Eike Gallmeier; Jörg Schirra; Hubert Wagner; Burkhard Göke; Rolf Lamerz
[A 27-year-old patient with recurrent Fever].
Medizinische Klinik (Munich, Germany : 1983) 2003;98(11):641-5.